Goodwin assisted Metagenomi on the matter. Preclinical biotech Metagenomi went public on the Nasdaq under the ticker “MGX”, raising $94 million by offering 6.25 million shares...
You must be a Standard 1 Year member to access this content.
Mintz advised Immunome, and Cooley and Goodwin advised Morphimmune. Immunome (Nasdaq: IMNM) and Morphimmune announced that they have entered into a definitive merger agreement. The Boards of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins, Torys LLP and Goodwin represented Triumvira Immunologics in the transaction. Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
